Firicabtagene autoleucel

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameFiricabtagene autoleucel
Drug Alias Namefiri-celCRG-022
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityCD22 modulators
TargetsCD22
Therapy Area/IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCargo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesCargo Therapeutics Inc
Active IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A